ইঙ্গিত ও ব্যবহার
Vinorelbin is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent, for the treatment of patients with metastatic NSCLC
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
In Combination with Cisplatin 100 mg/m2: The recommended dosage of Vinorelbine Tartrate is 25 mg/m2 administered as an intravenous injection or infusion over 6 to 10 minutes on Days 1, 8, 15 and 22 of a 28-day cycle in combination with cisplatin 100 mg/m2 on Day 1 only of each 28-day cycle.In Combination with Cisplatin 120 mg/m2: The recommended dosage of Vinorelbine Tartrate is 30 mg/m2 administered as an intravenous injection or infusion over 6 to 10 minutes once a week in combination with cisplatin 120 mg/m2 on Days 1 and 29, then every 6 weeks.Single Agent: The recommended dosage of Vinorelbine Tartrate is 30 mg/m2 administered intravenously over 6 to 10 minutes once a week.Pediatric Use: The safety and effectiveness of Vinorelbine Tartrate in pediatric patients have not been established.
পার্শ্বপ্রতিক্রিয়া
Most common adverse reactions (incidence ≥20%) are leukopenia, neutropenia, anemia, increased aspartate aminotransferase, nausea, vomiting, constipation, asthenia, injection site reaction and peripheral neuropathy.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment.Severe constipation and bowel obstruction, including necrosis and perforation, occur. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus.Extravasation can result in severe tissue injury, local tissue necrosis and/or thrombophlebitis. Immediately stop Vinorelbin and institute recommended management procedures.Neurologic Toxicity: Severe sensory and motor neuropathies occur. Monitor patients for new or worsening signs and symptoms of neuropathy. Discontinue for Grade 2 or greater neuropathyPulmonary toxicity and respiratory failure occur. Interrupt Vinorelbin in patients who develop unexplained dyspnea or have any evidence of pulmonary toxicity. Permanently discontinue for confirmed interstitial pneumonitis or ARDA.Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus and to use effective contraception.
নিষেধাজ্ঞা
Hypersensitivity to vinorelbine or other vinca alkaloids; severe current or recent infection (within last 2 wk); neutropenia; thrombocytopenia; severe hepatic impairment. Intrathecal admin. Do not give concomitantly with radiotherapy if liver is in treatment field. Pregnancy, lactation.